MedTrace Logo

Extension Study of MT-1303

NCT01890655 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 367

Last updated 2016-04-11

No results posted yet for this study

Summary

To evaluate the long-term safety and tolerability of MT-1303 in subjects with relapsing remitting multiple sclerosis (RRMS).

Conditions

  • Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

MT-1303-Low

DRUG

MT-1303-Middle

DRUG

MT-1303-High

Sponsors & Collaborators

  • Mitsubishi Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • Ludwig Kappos, MD · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Belgium
  • Bulgaria
  • Canada
  • Croatia
  • Czechia
  • Finland
  • Germany
  • Hungary
  • Italy
  • Lithuania
  • Poland
  • Russia
  • Serbia
  • Spain
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01890655 on ClinicalTrials.gov